Format

Send to

Choose Destination
Complement Ther Med. 2019 Aug;45:85-88. doi: 10.1016/j.ctim.2019.05.022. Epub 2019 May 22.

Methylsulfonylmethane for treatment of low back pain: A safety analysis of a randomized, controlled trial.

Author information

1
Mike O'Callaghan Military Medical Center, Nellis Air Force Base, Nevada, 89191, USA. Electronic address: paul.f.crawford.mil@mail.mil.
2
Mike O'Callaghan Military Medical Center, Nellis Air Force Base, Nevada, 89191, USA.

Abstract

OBJECTIVE:

To ensure that 16 weeks of methylsulfonylmethane (MSM) does not cause adverse effects in patients with the musculoskeletal disorders of osteoarthritis and back pain.

DESIGN:

We carried out a subgroup analysis on data from a randomized, double-blind, placebo-controlled trial, "The use of Methylsulfonylmethane (MSM) in the treatment of low back pain," to determine the safety of taking 6 g daily of MSM (OptiMSM®, Bergstrom Nutrition). We monitored metabolic parameters to determine whether MSM altered hematologic, liver or kidney function. We also monitored physiologic parameters of blood pressure and weight.

SETTING:

Family Medicine Residency, Mike O'Callaghan Military Medical Center.

MAIN OUTCOME MEASURES:

Metabolic parameters as measured by hematologic function - white blood cells (WBC), platelets, hemoglobin (Hb), glucose; liver function as measured by - total bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Physiologic parameters as measured by weight, diastolic (DBP) and systolic blood pressure (SBP); kidney function as measured by creatinine.

RESULTS:

Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.

CONCLUSION:

MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study.

KEYWORDS:

Methylsulfonylmethane; Pain; Safety

PMID:
31331587
DOI:
10.1016/j.ctim.2019.05.022

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center